Phase II Clinical Trial of Interleukin-2 in AD
Public ClinicalTrials.gov record NCT06096090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients With Mild to Moderate Alzheimer's Disease
Study identification
- NCT ID
- NCT06096090
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 86 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 29, 2025
- Completion
- Dec 29, 2025
- Last update posted
- May 22, 2024
2022 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Houston Methodist Research Institute | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Alzheimer Disease trials
Other public records listing Alzheimer Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT06940687: Neurophysiological Benefits of Live Music for Early Alzheimer's Patients and Their Caregivers Active, not recruiting
- NCT06808984: Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease Recruiting
- NCT07787182: A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease Not yet recruiting
- NCT07787169: A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Not yet recruiting
- NCT04517552: Investigation of Inflammation Using [C-11]-CS1P1 Active, not recruiting
- NCT07763392: Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06096090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2024 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06096090 live on ClinicalTrials.gov.